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Edited by Vladimir SkulachevAbstract Exposure of HL-60 cells to 1,25-dihydroxyvitamin
D3 (calcitriol) induces their diﬀerentiation into monocytes. This
terminal diﬀerentiation is associated with acquired resistance
to many proapoptotic stimuli. Here we show that diﬀerentiated
HL-60 cells undergo apoptosis upon curcumin treatment
although they retain resistance to apoptosis induced by a topoi-
somerase poison – etoposide. Curcumin induced changes of nu-
clear morphology, DNA fragmentation, release of cytochrome
c as well as caspase activation in both diﬀerentiated and undiﬀer-
entiated cells. Experiments performed in other laboratories sug-
gested that curcumin initiates apoptosis by DNA damage that
results from topoisomerase II poisoning. We measured cH2AX
expression, a marker of DNA double strand breaks, in both
undiﬀerentiated and diﬀerentiated HL-60 cells treated with cur-
cumin or etoposide. In etoposide-treated undiﬀerentiated cells
early cH2AX expression correlated with initiation phase of
apoptosis. In contrast, in curcumin-treated cells cH2AX expres-
sion correlated with apoptotic DNA fragmentation, which is
characteristic for the execution phase of apoptosis. Our experi-
ments show that curcumin overcomes the resistance of calci-
triol-diﬀerentiated HL-60 cells to DNA-damage-induced
apoptosis by activating other cell signaling pathways leading to
cell death of HL-60.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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The crucial feature of tumor cells which makes them so dan-
gerous to the host organism is their uncontrolled proliferation.
Among the phenotypic abnormalities in acute leukemia that
enable uncontrolled proliferation of these cells is their inability
to undergo terminal diﬀerentiation. Induction of diﬀerentia-
tion of leukemic cells is a promising therapeutic approach
[1,2]. Human promyelocytic HL-60 cell line provides a very
useful experimental model for studying molecular and cellular
events involved in leukemic cell diﬀerentiation. Upon treat-
ment with various compounds HL-60 cells are able to diﬀeren-Abbreviations: TPA, 12-O-tetradecanoyl-phorbol-13-acetate; ATRA,
all-trans retinoic acid; 9-cis-RA, 9-cis-retinoic acid; MTT, 3-(4,5-dim-
ethyldiazol-2-yl)-2,5-diphenyl tetrazolium bromide
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doi:10.1016/j.febslet.2006.07.038tiate into granulocytes (e.g., all-trans retinoic acid (ATRA), 9-
cis-retinoic acid (9-cis-RA)) or monocytes/macrophages (e.g.,
12-O-tetradecanoyl-phorbol-13-acetate (TPA), vitamin D3) [3].
As has been shown for several cell lines diﬀerentiation of leu-
kemic cells is accompanied by the emergence of resistance to
proapototic agents [4–10]. Therefore, cells which are at earlier
stages of diﬀerentiation could escape chemotherapy, thus caus-
ing tumor recurrence.
Apoptosis is a mode of cell death that can be induced,
among other factors, by chemotherapeutic drugs during cancer
treatment. Apoptotic cell death is regulated by a genetically en-
coded program that leads to characteristic morphological as
well as biochemical changes like cell shrinkage, formation of
apoptotic bodies and oligonucleosomal DNA fragmentation
in dying cells. During execution of the apoptotic cell death pro-
gram a cascade of proteolytic enzymes called caspases are acti-
vated. The most important and well recognized is caspase-3.
The molecular mechanism underlying the diﬀerentiation-in-
duced resistance to apoptosis remains elusive. It was shown
that diﬀerentiation of HL-60 cells along a monocytic pathway
induced by exposure to TPA correlated with resistance to
apoptosis induced by topoisomerase I and II inhibitors, cam-
ptothecin and etoposide, respectively. The inhibition of the
apoptotic pathway took place in the cytoplasm, downstream
of the speciﬁc damage site induced by the topoisomerase poi-
son [11]. Moreover, it was reported that during calcitriol-in-
duced diﬀerentiation of HL-60 cells, increased expression of
Mcl-1 protein – a member of Bcl-2 family – protected cells
against etoposide- or calcium ionophore-induced cell death [4].
Curcumin is a naturally occurring yellow pigment from the
rhizome of the perennial herb Curcuma longa. Turmeric, the
powder of rhizome, has been used for centuries in traditional
medicine. Moreover, curcumin is a potent chemopreventive
agent that inhibits tumor promotion in skin, oral, intestinal
and colon carcinogenesis. It has already been tested in ﬁrst
phase of clinical trials as a chemopreventive agent [12].
A number of observations show that curcumin is able to in-
hibit proliferation as well as to induce apoptotic cell death in
numerous cell lines established from malignancies like leuke-
mia and breast, lung, prostate and colon tumors [13]. The ex-
act molecular mechanism of curcumin-induced apoptosis
depends on the cell type and concentration of the drug used
in the experiments, but it is well documented that both main
signaling pathways leading to apoptosis – via mitochondria
and via death receptors – can be activated [13,14]. Although
much progress has been made in understanding the route of
apoptosis induced by curcumin, the primary site of its action
remains elusive. Some experiments suggest that curcumin canblished by Elsevier B.V. All rights reserved.
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[15,16] or through generation of free radicals [17] however, a
direct proof is lacking.
There are data showing that curcumin induces cell death by
modulating expression or activity of proteins that are involved
in the establishment of the apoptosis-resistance phenotype in
tumor cells. For example, curcumin-induced apoptosis in lung
cancer and prostate cancer cell lines correlated with decreased
expression of the antiapoptotic Bcl-2 and Bcl-XL proteins
[18,19], while induction of expression of proapoptotic Bax pro-
tein was observed in Ehrlich’s Ascites carcinoma upon curcu-
min treatment [20]. Bush et al. [21] reported suppression of
XIAP protein, which acts as a caspase inhibitor, in human mel-
anoma cells in response to curcumin treatment.
Our own experiments showed that curcumin is able to break
the apoptosis resistance in the P-gp+ acute leukemia cell line
CEM-A7+, in colon carcinoma LoVo cells [22] as well as in
myeloblastic leukemia HL-60 cell lines expressing either P-
glycoprotein (P-gp) encoded by the MDR1 gene, or multidrug
resistance-associated protein 1 encoded by the MRP1 gene
[23]. These observations prompted us to test curcumin as a
death-inducing compound in calcitriol-diﬀerentiated HL-60
cells.2. Materials and methods
2.1. Cell culture, induction of diﬀerentiation and cell treatment
Human acute myeloid leukemia subtype M2 (HL-60) cell line were
obtained from the European Type Culture Collection were cultured
in complete medium (RPMI 1640 supplemented with 10% heat inacti-
vated foetal calf serum, antibiotics, 2 mM L-glutamine) and kept at
37 C in humidiﬁed atmosphere (5% CO2 in air).
Calcitriol was kindly supplied by Prof. Andrzej Kutner from the
Pharmaceutical Research Institute in Warsaw. The compound was ali-
quoted and stored in glass ampoules under argon at 20 C in dark.
Prior to use calcitriol was dissolved in ethanol.
HL-60 cells were induced to diﬀerentiate by treatment with 100 nM
calcitriol for 4 days. Control cells were cultured in the same conditions
with the medium supplemented with an equal amount of ethanol.
Diﬀerentiated and undiﬀerentiated HL-60 cells were collected,
counted and adjusted to the density of 0.5 · 106/ml for treatment with
curcumin or etoposide. Curcumin (Cayman) was dissolved in 96% eth-
anol and etoposide was dissolved in DMSO and added to the medium
to a given ﬁnal concentration.
2.2. Flow cytometry analysis of induction of diﬀerentiation and apoptosis
Cell surface CD11b and CD14 were used as markers of monocytic
diﬀerentiation. Cells (2.5 · 105) treated with or without calcitriol were
incubated with anti-CD11b-FITC or anti-CD14-PE antibodies or con-
trol IgG (Becton Dickinson) for 30 min at 4 C and subjected to ﬂow
cytometry analysis.
For measurement of DNA content by ﬂow cytometry one million
cells were collected, washed and suspended in Nicoletti buﬀer (0.1% so-
dium citrate, pH 7.4, 0.1% Triton X-100, 50 lg/ml propidium iodide).
The subG1 fraction represents apoptotic cells.
Flow cytometric analyses were performed on FACSCalibur (Becton
Dickinson) using CellQuest analysis software.
2.3. Cell viability assay
Cell viability was measured by the 3-(4,5-dimethyldiazol-2-yl)-2,5-di-
phenyl tetrazolium bromide (MTT) assay as described by manufac-
turer.
2.4. Microscopy
Cell nuclei were stained with DAPI (30 nM) as described previously
[23] and analyzed in a ﬂuorescence microscope (Nicon) with a 60·
immersion objective. Images were acquired from randomly selected
ﬁelds.2.5. SDS–PAGE and Western blot analysis
Whole-cell protein samples were analyzed by SDS–PAGE using the
Laemmli method [24]. Cytochrome c level was measured in cytosol
fraction prepared according to methods described by Bielak-Mijewska
et al. [23]. The protocol used for Western blotting was as reported [23].
A monoclonal antibody against cytochrome c (1:500) (Pharmingen),
PARP (1:250) (Becton Dickinson) or b actin (1:10000) (Sigma) was
used. Detection was carried out with chemiluminescent reagent
(ECL) kit (Amersham Pharmacia Biotech).
2.6. Mitochondrial membrane potential measurement
One million of cells untreated or treated with curcumin or etoposide
was resuspended in 1 ml of RPMI medium and loaded with 100 nM
ﬂuorescent probe – tetramethyl rhodamine methyl ester (TMRM), dur-
ing 25 min at 37 C incubation prior to cytometric analysis. Flow cyto-
metric analyses were performed on FACSCalibur (Becton Dickinson)
using CellQuest analysis software.
2.7. DNA double-strand breaks (DSB) detection
DNA double-strand breaks were measured by an anti-c-H2AX his-
tone assay with an anti-phospho-Histone H2A.X (Ser-319) antibody
(Upstate Cell Signalling, Poland) at 2 lg/ml. Staining was performed
according to the producer’s recommendation and analysis was per-
formed by ﬂow cytometric measurement using CellQuest analysis soft-
ware.
If not indicated all reagents were purchased from Sigma.3. Results and discussion
3.1. Curcumin decreases survival of calcitriol diﬀerentiated
HL-60 cells
HL-60 cells were induced to diﬀerentiate along the mono-
cytic pathway by 96 h-incubation with 100 nM calcitriol,
which resulted in expression of monocytic diﬀerentiation
markers – CD11b and CD14 – in 80% of cells. Cell cycle anal-
ysis demonstrated that induction of diﬀerentiation was accom-
panied by inhibition of proliferation, since the majority of
calcitriol-treated cells were in G1 phase of the cell cycle
(Fig. 1). In order to estimate the cytotoxic eﬀect of curcumin,
diﬀerentiated and undiﬀerentiated HL-60 cells were treated
with various concentrations of curcumin and cell viability
was measured using MTT assay. In parallel the same cell via-
bility measurement was performed in undiﬀerentiated and dif-
ferentiated cells treated with a topoisomerase II inhibitor,
etoposide. Diﬀerentiated HL-60 cells have been shown by oth-
ers to be resistant to the cytotoxic activity of etoposide
[4,11,25,26] and consequently we used etoposide in our exper-
iments as a positive control for the cell death resistance pheno-
type of diﬀerentiated cells. As expected, 80% of the
diﬀerentiated cells remained viable after 24 h of treatment with
20 lM etoposide, while their undiﬀerentiated counterparts
treated with even a 10 times lower concentration of the drug
showed a dramatic loss of cell viability. In contrast to the sit-
uation with etoposide, curcumin-treated cells showed a signif-
icant decrease of cell viability regardless of their diﬀerentiation
status. The changes observed in both undiﬀerentiated and dif-
ferentiated HL-60 cells were dose-dependent (Fig. 2A). The
time course of changes in cell viability of HL-60 cells treated
with 50 lM curcumin or, in comparison, with 20 lM etoposide
is shown in Fig. 2B. Upon curcumin treatment both undiﬀer-
entiated and diﬀerentiated cells exhibited a signiﬁcant loss of
viability already after 3 h of incubation, which decreased at a
later time points. Etoposide decreased the viability of undiﬀer-
entiated HL-60 cells to a similar extent as curcumin, while no
Fig. 1. Expression of diﬀerentiation markers (A) and DNA content
analysis (B) of untreated- and calcitriol-treated HL-60 cells. HL-60
cells were treated with 100 nM calcitriol for 4 days, then expression of
CD11b and CD14 cell surface markers (A) as well as DNA content
were determined by ﬂow cytometry (B).
Fig. 2. Viability of undiﬀerentiated and diﬀerentiated HL-60 cells treated with
cell viability upon etoposide or curcumin treatment were estimated using M
(treated vs. untreated) using one-way ANOVA followed by non-parametric M
signiﬁcance.
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3.2. Curcumin induces apoptosis of diﬀerentiated HL-60 cells
We showed previously that 50 lM curcumin treatment of
HL-60 cells induces apoptosis characterized by chromatin con-
densation, formation of apoptotic bodies and DNA fragmen-
tation [27]. Similar results were obtained also by others
[28,29]. In order to know whether the decreased viability of dif-
ferentiated HL-60 cells described in the preceding paragraph
also results from curcumin-induced apoptosis, we analyzed nu-
clear morphology. Staining of HL-60 cells with the ﬂuorescent
dye DAPI revealed similar changes in the nuclei in both undif-
ferentiated and diﬀerentiated cells upon treatment with curcu-
min. After 12 h of treatment the majority of cells showed
apoptotic chromatin condensation and fragmentation. In con-
trast, most of etoposide-treated diﬀerentiated cells retained
their normal nuclear morphology with uniform DNA staining,
although some cells with altered nuclear morphology were also
recognized. At the same time almost all undiﬀerentiated HL-60
cells displayed apoptotic nuclear morphology upon etoposide
treatment (Fig. 3A).
SubG1 fraction which corresponds to apoptotic cells mea-
sured after 24 h of treatment accounted for 20% in etopo-
side-treated and for 50% in curcumin-treated diﬀerentiated
HL-60 cells. In undiﬀerentiated cells after etoposide treatment
the amount of subG1 fraction achieved even 70%, although
after curcumin treatment it slightly exceeded 20% (Fig. 3B).etoposide or curcumin. Dose- (A) and time- (B) dependent changes of
TT assay. Data are expressed as means ± S.D. and compared in pairs
ann–Whitney U-test, **P < 0.01 was considered to indicate statistical
Fig. 3. Apoptotic symptoms in etoposide- or curcumin-treated cells. (A) Nuclear morphology of diﬀerentiated and undiﬀerentiated cells after
12-h treatment with etoposide or curcumin; (B) the percentage of subG1 fraction in diﬀerentiated or undiﬀerentiated HL-60 cells measured after
24-h treatment with curcumin or etoposide.
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of curcumin-treated HL-60 cells could be explained by induc-
tion of apoptosis in cells that are in G2 or M phase of cell cy-
cle. DNA fragmentation in those cells do not contribute to
increase in subG1 fraction since they possess still more then
2N DNA [30]. More over after 24 h treatment with curcumin
cells undergo secondary necrosis that follows apoptosis ob-
served at an earlier time point. This reﬂects higher sensitivity
of proliferating HL-60 cells to curcumin treatment conﬁrmed
also by cell viability measurement (Fig. 2). DNA content of ne-
crotic cells measured by ﬂow cytometry using propidium io-
dide staining and presented as DNA frequency histogram
resembles DNA histogram obtained form control cells [31].
Thus it is possible that increasing fraction of necrotic cells re-
sults in lower amount of cells in subG1 fraction observed in
undiﬀerentiated cells treated with curcumin.
Western blot analysis of cytochrome c (cyt c) released to
cytoplasm proved that apoptosis induced by curcumin under-
go via mitochondrial apoptotic pathway. Namely, either in dif-
ferentiated or undiﬀerentiated HL-60 cells already after 6 h of
curcumin treatment the elevated level of cyt c in cytoplasmic
fraction was observed. The amount of detected cyt c increased
signiﬁcantly with time. Cytochrome c release was observed
also in other experimental models in which curcumin was used
as a death-inducing agent [29,32,33]. In contrast, etoposide in-duced a substantial cyt c release only in non-diﬀerentiated HL-
60 cells (Fig. 4A).
Releasing of cyt c from mitochondria activates apoptosome
and following activity of caspase 3. Accordingly, Western blot
analysis of PARP cleavage, a substrate for caspases 3 and 7,
showed diﬀerent levels of its cleaved form in curcumin- and
etoposide-treated diﬀerentiated cells (Fig. 4B). Curcumin in-
duced cleavage of PARP in diﬀerentiated cells after 12 h of
treatment. The fraction of the cleaved form of PARP increased
with time. A similar time course of changes was observed in
undiﬀerentiated HL-60 cells, although the cleaved form of
PARP dominated already at the 12th hour of curcumin treat-
ment. Etoposide-treated diﬀerentiated cells showed only a low
level of cleaved PARP after 6 h, and it did not increase with
time. In contrast, treatment of undiﬀerentiated cells with eto-
poside caused a very rapid PARP degradation, starting already
after 3 h, which became complete after 12 h (Fig. 4B). This re-
sult further conﬁrms that curcumin induce apoptotic cell death
program in diﬀerentiated HL-60 cells that ends with eﬀector
caspases activation and degradation of substantial cell sub-
strates. Altogether these data prove that apoptosis resistance
of diﬀerentiated cells is not a consequence of defects in activa-
tion of apoptotic mitochondrial pathway since curcumin was
able to induce cyt c release as well as activate eﬀector caspases
in diﬀerentiated cells.
Fig. 4. Apopotic pathway in etoposide- or curcumin-treated HL-60 cells. Time course of cytochrome c release (A) and PARP cleavage (B) in
curcumin- or etoposide-treated undiﬀerentiated and diﬀerentiated cells determined by Western blotting. Mitochondrial membrane potential of
diﬀerentiated and undiﬀerentiated HL-60 cells treated for 12 h with curcumin or etoposide and stained with ﬂuorescence probe TMRM – indicator of
mitochondrial membrane potential (C).
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sipation of mitochondrial membrane potential (MMP) and
opening unspeciﬁc permeability transition pore (PTP) allowing
for release of cyt c [34]. However, cyt c can also be released by
speciﬁc channel formed by Bax and Bak proteins [35]. In
HL-60 cells we observed the evident decrease of MMP after
etoposide, but not curcumin treatment. Either curcumin or
etoposide did not induce dissipation of MMP in diﬀerentiated
HL-60 cells (Fig. 4C). This is consistent with our previous
experiments showing complete closure of PTP produced by
curcumin in Jurkat cells [36]. It is widely accepted that perme-
abilization of outer mitochondrial membrane and releasing of
cyt c from the intermembrane space is a key initiative step in
the apoptotic process. Several hypotheses exist explaining the
possible mechanism of outer mitochondrial membrane perme-
abilization. One of it argues that proapototic protein Bax stim-
ulates cyt c release by forming pores in outer mitochondrial
membrane that are independent from mitochondrial perme-
ability transition and hence do not cause loss of mitochondrial
membrane potential [37]. It can be supposed that in curcumin-
treated either undiﬀerentiated or diﬀerentiated HL-60 cells cyt
c is released by these speciﬁc channels formed by proapoptotic
Bcl-2 family member Bax. Recently Rashmi et al. [33] has dem-
onstrated that Bax-deﬁcient HCT116 human colon cancer cells(Bax/) were resistant to curcumin-induced apoptosis and
did not show the release of cyt c upon curcumin treatment
whereas their wild-type HCT116 (Bax+/+) counterparts did.
Presented data demonstrate that curcumin induces apoptosis
in diﬀerentiated HL-60 cells which are otherwise resistant to
apoptotic stimuli such as anti-cancer drugs [4,10,11], death
receptor agonist [38] or irradiation [39].
3.3. Curcumin-induced cell death is not caused by double-strand
DNA breaks
There are some reports showing that curcumin could act as a
DNA topoisomerase II poison [16]. It is well documented that
compounds which act as topoisomerase II poisons, like etopo-
side, stabilize transient intermediates of topoisomerase reac-
tions and cause single- and double-strand DNA breaks
(DSB) [40]. The latter are among the most dangerous forms
of DNA damage, being very diﬃcult to repair and potentially
lethal [41]. It has been claimed that DNA damage induced by
topoisomerase II poisoning could be a possible mechanism by
which curcumin initiates apoptosis [15]. Since the results of our
experiments showed that diﬀerentiated HL-60 cells are sensi-
tive to curcumin-induced cell death whereas they are resis-
tant to treatment with etoposide, a typical topoisomerase
poison, we compared the DNA damage caused by these two
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lated histone cH2AX expression in undiﬀerentiated and diﬀer-
entiated HL-60 cells. Phosphorylation of the H2AX histone
(cH2AX) is one of the ﬁrst events that take place at the
DSB and marks the actual site of double-strand DNA damage
[42]. cH2AX-recognizing antibodies have become a gold stan-
dard for the detection of DSB. We also estimated apoptotic
DNA fragmentation in etoposide- and curcumin-treated cells
(measured as subG1 fraction) in order ﬁnd out whether the
apoptotic cell death induced by drug treatment is a conse-
quence of drug induced DSB. For these experiments we used
ﬁrst 20 lM etoposide. As described in previous paragraphs
20 lM etoposide induced apoptosis in undiﬀerentiated cells
showing little eﬀect on viability of diﬀerentiated cells. We ob-Fig. 5. Expression of cH2AX and subG1 DNA content in undiﬀerentiate
Undiﬀerentiated and diﬀerentiated HL-60 cells were treated with 2 lM or 20 l
histon H2AX phosphorylated on Ser-139 (cH2AX) was measured using ﬂow
(subG1 fraction) was estimated. Data are expressed as means ± S.D. and com
by non-parametric Mann–Whitney U-test, **P < 0.01 was considered to indiserved that the majority (90%) of etoposide-treated undiﬀeren-
tiated HL-60 cells express cH2AX within 3 h of incubation and
this high level of expression lasted until 12 h of incubation.
This concentration of etoposide (20 lM) induced very rapid
apoptosis-related DNA fragmentation of undiﬀerentiated cells
expressed as the percentage of cells in subG1 fraction
(Fig. 5A). An elevation of cH2AX expression in apoptotic cells
with fragmented DNA was also observed in other experimen-
tal models [43,44]. In order to discriminate between cH2AX
expression correlated with the induction phase of apoptosis
and the expression initiated by DNA fragmentation in etopo-
side-treated undiﬀerentiated HL-60 cells, we tested cH2AX
expression after lower concentration of the drug (2 lM). We
showed that cH2AX expression, which increases dramaticallyd and diﬀerentiated HL-60 cells treated with etoposide or curcumin.
M etoposide or 50 lM curcumin and the percentage of cells expressing
cytometry. In parallel the percentage of cells with DNA fragmentation
pared in pairs (treated vs. untreated) using one-way ANOVA followed
cate statistical signiﬁcance.
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which in turn stays at a low level for at least 6 h of incubation
(Fig. 5C). On these bases we can assume that etoposide-in-
duced DNA damage is a cause of subsequent cell death. There
are conﬂicting data in the literature concerning the susceptibil-
ity to DNA damage in apoptosis-resistant diﬀerentiated HL-60
cells upon treatment with genotoxic drugs. Solary et al. [11]
measured single-strand DNA breaks (SSB) in TPA-diﬀer-
entiated HL-60 cells upon treatment with topoisomerase
inhibitors. They showed that etoposide induced SSB in diﬀer-
entiated cells, although to a lesser extent then in undiﬀerenti-
ated cells, while m-AMSA was almost equally eﬃcient in
both cell types. In contrast Zwelling et al. [45] found that eto-
poside-induced DNA cleavage was reduced 10-fold in HL-60
cells treated with PMA. In our experimental model treatment
of diﬀerentiated HL-60 with 20 lM etoposide caused a signif-
icant and rapid increase of cH2AX expression, whereas the
percentage of cells in subG1 initially stayed at low level and la-
ter increased only marginally (Fig. 5B). The induction of
cH2AX was weaker than in undiﬀerentiated cells and it de-
creased after 6 h of incubation, which could results from eﬃ-
cient repair of damaged DNA. Using a lower concentration
of etoposide (2 lM) we found almost no cH2AX expression
in diﬀerentiated cells (Fig. 5D). The presented data suggest
that diﬀerentiated cells are sensitive to drug-induced DNA
damage although they are resistant to drug-induced apoptosis.
However, diﬀerentiated cells are not equally sensitive to the
DNA-damage-inducing activity of a topoisomerase poison as
their undiﬀerentiated counterparts are. Ketley et al. [46] sug-
gested that diﬀerentiated cells, which are arrested in G1 phase
of the cell cycle, could be more resistant to DNA damage be-
cause they simply have more time to repair it. This feature of
diﬀerentiated cells could explain our observation that the lower
dose of etoposide causes quickly-repairable damages, which we
were not able to detect using a cH2AX as a DSB marker. We
cannot exclude that diﬀerentiated cells are also less damaged
upon a given dose of the drug.
Also curcumin was able to induce phosphorylation of a his-
ton H2AX in undiﬀerentiated and diﬀerentiated HL-60 cells
but the time course of this induction diﬀered from that induced
by etoposide. In both undiﬀerentiated and diﬀerentiated cells
the percentage of cells expressing cH2AX increased gradually
and correlated with the apoptotic DNA fragmentation mea-
sured as the number of cells in subG1 fraction. After 6 h of
treatment of undiﬀerentiated cells the same percentage of cells
with measurable cH2AX expression and DNA fragmentation
was observed (Fig. 5E). In diﬀerentiated HL-60 cells cH2AX
expression reached a high level only after 12 h of incubation
with curcumin, which corresponds to curcumin-induced DNA
fragmentation (Fig. 5F). Since curcumin did not induce a rapid
elevation of cH2AX expression preceding DNA fragmentation
in either undiﬀerentiated or diﬀerentiated HL-60 cells we con-
clude that topoisomerase II poisoning, and consequently
DNA damage, are not a primary site of the proapoptotic activ-
ity of curcumin. Our results do not conﬁrm the data presented
by Martin-Cordero et al. [15], who claimed that DNA damage
induced by topoisomerase II poisoning is a possible mechanism
by which curcumin initiates apoptosis. Their conclusion was
based on an in vitro assay of DNA cleavage with puriﬁed topo-
isomerase II and correlated with the observed cytotoxic eﬀect of
curcumin on diﬀerent cell lines. Also Snyder and Arnone [16]
demonstrated that curcumin was able to enhance bleomycin-in-duced chromosome damage tested in the micronucleus-forma-
tion assay. That activity of curcumin was antagonized by
topoisomerase II catalytic inhibitors, suggesting that curcumin
is likely a topoisomerase II poison. In contrast to the results ob-
tained by Martin-Cordero et al. [15], curcumin did not poison
puriﬁed topoisomerase II under the conditions of the in vitro
assay used in the experiments of Snyder and Arnone [16]. It
should be emphasized that the results obtained by the two
groups do not constitute a direct proof that curcumin-induced
double strand DNA damage caused by topoisomerase II poi-
soning leads to apoptotic cell death.
Regardless of the mechanism of curcumin action, the results
of our experiments show that this natural polyphenol is able to
overcome diﬀerentiation-induced resistance of HL-60 cells to
apoptosis. Using cH2AX as a marker of double-strand breaks
we prove that the curcumin-induced cell death does not involve
DNA-damage-initiated signaling pathways, to which diﬀeren-
tiated HL-60 cells are highly resistant.
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